Background: This study provides estimates of population-based relative survival in Spain for nine major cancers and reports results on cancer survival by region, gender and age group.
introduction
The study of population-based cancer survival affords valuable knowledge for assessing health care performance in patients diagnosed with malignant tumours. The difficulty of ascertaining population survival lies primarily in having reliable and valid data on population incidence, and secondly, in the accuracy and completeness of follow-up. Once these barriers have been overcome, in order to make comparisons between different populations in the same incidence period it is also necessary to standardise the information, using a common follow-up period and similar strategies for ascertaining vital status.
Here in Spain, survival rates have previously been published in the EUROCARE study [1, 2] , and only in Catalonia and Navarre has population-based relative survival (RS) been analysed in depth [3, 4] . Researchers have investigated differences in cancer survival in some countries, namely: the ITACARE study [5] revealed regional differences in survival that may reflect unequal provision of care between northerncentral and southern Italy; in England, Wales and Scotland, cancer survival was reported to be closely related to level of deprivation [6] [7] [8] ; and in Japan [9] , regional differences in cancer survival were found for stomach and lung cancer. Geographical differences have also been analysed worldwide original article *Correspondence to: María-Dolores Chirlaque, Consejería de Sanidad, Servicio de Epidemiología, Ronda de Levante 11, 30008 Murcia, Spain. Tel: +34-968-366195; Fax: +34-968-366656; E-mail: mdolores.chirlaque@carm.es [10] , among and within European countries [1] and in the USA [11] . In Spain, a geographical gradient has been observed in the degree of socioeconomic development, with regions in the north-east registering a higher gross domestic product (GDP) than do those in the south-west [12] .
However, no studies on regional differences in cancer incidence or survival have been undertaken to date, though municipal cancer mortality figures are available [13] .
Spain's National Cancer Strategy [14] seeks to promote and protect health, improve early detection and provide optimal care and treatment, thereby achieving an impact on quality of life and potential cures for cancer. Accordingly, it is both necessary and relevant for citizens, health professionals and the National Health Service (NHS) to provide countrywide population survival estimates-at least in the case of major cancers-and to furnish results on cancer survival by region. Indeed, this was the aim of our study, which analysed survival data stratified by sex for nine major tumours from eight regions.
patients and methods

study population
This study targeted eight Spanish regions which together have >7 million inhabitants covered by population-based cancer registries. These regions are located in the north (Basque Country and Navarre), east (Girona, Tarragona and Castelló n) and south (Albacete, Murcia and Granada) of Spain, and represent 17% of the total population. The eight participant cancer registries regularly publish their data in Cancer Incidence in Five Continents (CIFC) monographs [15] , are members of the European Network of Cancer Registries [16] and collaborate in the EUROCARE study [1] . Standard data-quality indices used in population-based cancer registries were published in CIFC-IX for the period 1998-2002, and the registries included in this study obtained good global quality indicators with high coverages. These registries have been operating successfully for >15 years.
data collection and follow-up
Data pertaining to the eight participant cancer registries were first retrieved from the EUROCARE-4 database for the period of diagnosis, 1995-99, and subsequently updated in several respects. First, each region completed the data information: Murcia added the incident year 1999 (versus 1998 in EUROCARE-4); Albacete included cases for the eight cancer sites in both sexes (the EUROCARE-4 dataset solely covered breast in women and lung in men); most of the registries continued the follow-up until December 2004 (versus December 2003 in EUROCARE-4). Secondly, all the registries revised their follow-up procedures so as to obtain more accurate information on vital status. This was feasible thanks to Spanish cancer registries' recently acquired capability of linking cancer cases to mortality data centrally collected and registered in the National Death Index (NDI) [17, 18] .
Follow-up was conducted using common criteria for collection of variables at all centres. To ascertain vital status directly, a check was run on different data sources. The data source used in all registries to complete follow-up was the NDI. When a case was not found in the NDI, 'alive' vital status was not assigned. Other sources, such as the social security database (belong to the NHS), hospital clinical records, primary-care records and municipal censuses, were used if available to the registry in question. Linkage procedures with the various data sources were implemented at the respective registries.
Data quality was verified in all cases, using both the IARC check [19] and EUROCARE rules [20] . After all resulting errors or warning messages had been duly reviewed by cancer registry staff, cases with missing, invalid or inconsistent date, sex, site, morphology or behaviour fields were coded as errors and excluded from the survival analysis.
cancer cases
Patients aged >14 years with nine types of cancer were included in the analysis and coded according to the International Classification of Diseases for Oncology, third edition (ICDO-3) [21] . Primary-site codes were C18 (colon), C19-21 (rectum-anus), C33-34 (trachea, bronchus and lung), C50 (breast), C56 (ovary), C61 (prostate) and C62 (testis), with haematological tumours (morphology codes 9590-9989) being excluded in all cases. Melanoma of skin corresponded to morphology 8720-8790 and site C44, and Hodgkin's lymphoma to morphology 9650-9667. Since all cases were invasive malignant tumours, in situ and uncertain tumours were excluded. While six regions participated with the full nine cancer sites selected for analysis, Castelló n, which has a monographic breast cancer registry, participated only in analysis of female breast cancer, and Granada provided data for all cancer types except prostate.
Cases diagnosed during the period 1995-99 were followed up until 31 December 2004. The variables used were sex, date of birth, date of diagnosis, date of follow-up and vital status (alive, dead, censored), topography, morphology, basis of diagnosis and sequential tumour number. The age groups chosen for cancer survival analysis were those used for the international standard cancer patient population (international standard for cancer survival analysis/ICSS) [22] . Only the first-diagnosed malignancies in any patient were selected. Cases known by death certificate only and diagnosed at autopsy were excluded from the survival analysis.
The databases of the eight cancer registries are registered with the Spanish Data Protection Authority [23] as stipulated by law. From the outset, all data collected in the dataset for survival analysis was anonymous and so no ethical approval was required [24] .
statistical methods
The maximum likelihood approach was applied to individual records [25] to estimate RS, using the STREL survival analysis algorithm [Cancer Research UK Survival Group (2006), version 6. Non-Communicable Disease Epidemiology Unit, London School of Hygiene and Tropical Medicine, UK] implemented in Stata software (Release 10; Stata corp., college Station, TX, USA). Life tables by single year of age, sex and region were obtained for each period, and survival probabilities were estimated annually.
RS is the ratio of observed survival to survival that would have been expected if cancer patients had had the same all-cause mortality in each period as the general population of the same age, sex and region. Hence, RS reflects excess mortality among cancer patients. RS at 5 years (5y-RS) from diagnosis is shown by region, sex, cancer site and age group. Survival estimates were adjusted using the ICSS and applying the traditional method for international comparisons, and the alternative method proposed by Brenner et al. [26] for Spanish regional comparison. For some cancer sites and regions, age-standardised 5y-RS could not be estimated due to the low numbers of cases or deaths occurring during some post-diagnosis periods among certain age groups.
Traditional age adjustment is often unsuccessful if data within single age group are sparse. In contrast, the method proposed by Brenner et al. [26] does not require calculation of age-specific RS. Instead, weights are first individually assigned to all cancer patients and survival analysis using weighted individual data is then carried out (for fuller details on the advantages and disadvantages of the above methods see Pokhrel and Hakulinen [27, 28] and Brenner [26, 29] , among others). RS estimates for the eight Spanish regions combined were obtained by pooling all cancer patients.
A statistical test was applied to explain any significant geographical variation in 5y-RS. The test assumed a linear relationship, Log[-log(S ar )] = a a + b r, where S ar are the 5-year cumulative RS probabilities for the age group a and the region r. The age and region effects, a a and b r , were estimated by performing a variance-weighted linear regression, and the weights used for the regression were the inverse of the variances of Log[-log(S ar )]. Similar models have been used previously [7, 30] . The significance of the region effect was evaluated by comparing the likelihood ratio test for the above-described model with the model including only the age effect. A significant P value of <0.05 indicated heterogeneity in 5y-RS between regions.
results
The characteristics of the cancer cases diagnosed in the period 1995-99 and included in the analysis are shown in Table 1 . The dataset from the Spanish cancer registries that participated in this study comprised a total of 57 622 incident cases. After excluding 43 cases due to errors, 2435 for being second or subsequent to primary cases, 1871 cases known only via death certificates and 42 diagnosed incidentally at autopsy, there were 53 227 cases for survival analysis. The proportion of cases censored after <5 years' follow-up was 2%. As many as 90% of cases were microscopically verified, except for lung (87.7%), with this figure rising to 100% in melanoma of the skin, testicular cancer and Hodgkin's lymphoma.
For the eight Spanish regions combined, the malignant tumour registering the highest 5y-RS was that of testis, with rates of close to 95% (Table 2 ). While melanoma of the skin showed better prognosis in women than it did in men (Figure 2) , survival in Hodgkin's lymphoma was similar for both (85%-86%). Sex-related differences were also observed for lung cancer, with survival being very low in general but even lower among men than among women. Colon and rectal cancer registered a moderate RS of up to 50%, which was similar across the sexes. RS adjusted by Brenner's method revealed higher survival for all tumour types among women, with the single exception of rectal cancer.
Pooled 5y-RS results by tumour and age group for all the regions combined are shown in Table 2 for both sexes, and in Figure 1 for men and women separately. In general, for the nine cancers selected, 5y-RS decreased with age. This downward slope was more pronounced for ovarian cancer. In testicular cancer, RS could only be calculated in the 15-44 age group (94.4%, 95% CI 91.3% to 96.4%) in view of the fact that 92% of all cases were in this age range. In prostate cancer, the age gradient was equally marked, declining from 72.9% (95% CI 65.4% to 79.1%) in the youngest age group to 52.0% (95% CI 42.0% to 61.1%) in the oldest. Whereas colon and rectal cancer registered a similar age-related RS, the range of variation was higher in the latter. The lung cancer survival rate declined from 20% in the 15-44 age group to 5% among those aged >74 years. This range was different by sex. Women diagnosed with breast Figure 1 to be completed. Table 3 shows the results for crude and Brenner agestandardised 5y-RS by tumour in the Spanish regions, and Figure 2 depicts Brenner age-adjusted 5y-RS stratified by sex. In colon and rectal cancer, Murcia and Granada (adjacent regions) registered the highest and the lowest RS, respectively. In lung cancer, Navarre had an RS that was twice that of Granada. While Castelló n recorded the highest RS for female breast cancer, the lowest was observed in Albacete. Insofar as ovarian cancer was concerned, Navarre had the lowest and the Basque Country the highest RS. Prostate cancer registered the highest values in Girona and the lowest in Albacete. In the case of testicular cancer and Hodgkin's lymphoma, RS could not be calculated in certain regions. Lastly, RS for melanoma of the skin was highest in Tarragona and lowest in Navarre.
The test for homogeneity among regions in terms of 5y-RS for cancer showed no geographical variation in rectal cancer for either sex, or in colon cancer for women. No homogeneity was observed for: prostate and colon cancer in men; lung cancer and melanoma in both sexes; breast cancer in women (Table 4) . In ovarian tumours, no regional differences were detected. Men, in general, showed heterogeneity in cancer survival for most tumours (colon, lung, prostate and melanoma).
discussion
This study ascertained population-based RS rates for cancer of the colon, rectum, lung, breast, ovary, testis, prostate, cutaneous malignant melanoma and Hodgkin's lymphoma among patients diagnosed in selected areas of Spain, over the period 1995-99. Lung cancer not only had the poorest prognosis (5y-RS, 10%), which was slightly better among young adults and women, but was also the tumour to register the largest maximum-to-minimum RS ratio between regions, with the rate for Navarre being double that for Granada. Colon and rectal cancer, with moderate survival rates of 54.7% and 50.2% respectively, and female breast cancer (83%) were the tumours that registered the lowest inter-regional ratios (<1.3). Ovarian cancer displayed a discrete survival of 43%, which was far lower among the oldest age groups. Prostate cancer had an intermediate survival rate of 76%, rising to close on 80% in the 45-74 age group, with rates ranging from highest in Girona to lowest in Albacete. Testicular cancer presented the best prognosis with a 5y-RS of 95%, reflecting the fact that, in most cases, this can be cured by adequate treatment; the low number of cases and the fact that these were concentrated among the 15-44 age group meant that a wider range of results could not be obtained. In the case of melanoma of the skin, the sexrelated difference in 5y-RS was >10% for women. Hodgkin's lymphoma registered an RS of 85%, rising to 92% among young adults.
Minor differences in survival were detected between Spanish and European adults [31] for the tumours targeted. When agestandardised 5y-RS was compared using the traditional method, there was <1% difference for most cancers [e.g. colorectal 53.5% and 53%, lung 10.2% and 9.7%, female breast 79.5% and 79.8%, ovarian 34.2% and 35.1% for Europe and Spain (data not shown) respectively] and <2% difference for the remainder. In line with other studies [32] [33] [34] , survival decreased with age at diagnosis, with the exception of breast and prostate cancer, in which survival rose, levelled off and then declined over the age span. Women registered higher survival than did men for all tumours analysed except rectal cancer. Similarly, women had a marked advantage in 5y-RS in melanoma of the skin and lung cancer. In the EUROCARE-4 European pool [35] , this advantage proved significant in melanoma and Hodgkin's lymphoma. In colorectal cancer too, the Concord study reported better survival for women in Europe, the USA and Oceania.
Survival in colorectal cancer in Spain is close to that in other European countries (Iceland, The Netherlands and Italy) [1] and, in a world context, is slightly above the median [10] .
Results from the US Surveillance, Epidemiology and End Results (SEER) programme [11] , however, showed a 10-point higher RS percentage than in Spain and Europe. As noted above, lung cancer registered the higher differences between Spanish regions, with a range of variation from 6.1 to 12.4 (this same range in Europe went from 7.9 in Denmark to 16.5 in Belgium), and no improvement was observed in relation to the 1990-94 survival rates [2] , partly due to better completeness of follow-up. Differing degrees of development of breast cancer screening programmes and disease management might go some way to explain the slight difference in survival by region. Ovarian cancer is a tumour that is usually diagnosed at advanced stages or ages, both of which are strongly associated with poorer survival, as is shown by results from Victoria (Australia) [36] whereby women aged <45 years had an RS of close to 70% versus <20% among women aged >75 years. Identical results were observed in Spain by age group. The 
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Spanish age-adjusted 5y-RS for prostate cancer in incident cases from 1995-99 was 74.2%, an appreciable increase over the previous period (RS of 65.5% for incident cases from 1990-94) [2] , an outcome possibly influenced by the introduction of prostate-specific antigen testing. Moreover, RS of >70% was reported for all but the oldest age groups. In all, 84% of Spanish original article Annals of Oncology subjects with invasive melanoma of the skin can expect to survive their cancer for at least 5 years. Like other studies [37] [38] [39] , we found that survival was better among women than men, yet these differences are not completely understood; the better prognosis in countries with high incidence is related to greater awareness, leading in turn to early detection of lesions. Survival after Hodgkin's lymphoma is generally favourable, with RS of 85% being observed for Spain, a rate similar to the European mean.
Although the results only reflect the population covered by the eight registries, these could nevertheless be looked upon as an approximation of cancer survival in Spain. The important issue of whether mean survival figures by geographical region are representative of wider areas as a whole (e.g. European countries versus Europe; areas included in the SEER programme versus the USA) has been addressed elsewhere [11, 40] . In our study, Spanish areas with different levels of socio-economic development were represented, so that in GDP terms, half the regions were lower and the other half higher than the mean [12] . No clear pattern between north and south or between wealthier and poorer regions was in evidence.
To our knowledge, this is the first analysis of population cancer survival by region in Spain using standard quality procedures. Cancer registries have standardised data in accordance with international rules, and improved the completeness of their follow-up procedures. The quality indicators calculated were better than the European average in EUROCARE-4, meaning that differences in cancer survival are unlikely to be entirely due to problems in data quality. However, the influence of linkage procedures cannot be ruled out.
The inclusion of eight population-based registries enabled us to examine cancer survival across Spain for nine major cancers, which were selected for being common or potentially curable. Although cases from eight cancer registries were included, in infrequent tumours, such as testicular cancer and Hodgkin's lymphoma, regional differences could not be examined. Another limitation was the influence of regions with a high number of cases in the overall estimate, such as the Basque Country with 37% of total cases.
We were unable to make a more in-depth assessment of differences in survival by stage at diagnosis with more detailed data because this information was not routinely collected by all registries. For those cancers in which prognosis depends mainly on stage at diagnosis (breast, colorectal, etc.), the ratio between regions was low. The greatest difference was observed for lung cancer, where primary prevention is the most effective tool for control.
In conclusion, cancer survival rates in Spain displayed better prognosis in females, mainly in the case of melanoma of the skin and lung cancer. Breast and prostate cancer registered lower survival in young than in middle-aged adults. The greatest decline over the age span was observed for ovarian cancer and Hodgkin's lymphoma. The worst prognosis was for lung cancer and the best for cutaneous melanoma, with breast, prostate and Hodgkin's lymphoma displaying favourable and colon, rectum and ovary unfavourable prognoses. The regional differences identified should be studied in greater depth to detect possible goals for improvement of cancer care. Further updated analyses are currently being undertaken to extend knowledge of survival in Spain. 
